Insomnia Drug Lemborexant Shows Promise in Slowing Alzheimer's Progression
A study published in Nature Neuroscience has revealed promising results for the insomnia drug Lemborexant in potentially slowing down Alzheimer's disease progression. Developed by Eisai, the medication is currently approved for treating insomnia but has shown neuroprotective effects in preclinical research.
The study, conducted by academic institutions and not funded by the pharmaceutical industry, found that Lemborexant could reduce the accumulation of toxic tau proteins and preserve brain structure in Alzheimer's disease models. Chronic sleep disturbances are known to increase the risk of developing Alzheimer's and are linked to its progression. In Alzheimer's, tau proteins clump together, disrupting nutrient and information flow within brain cells. Lemborexant works by targeting the orexin signaling pathway, which regulates wakefulness and has been linked to neurodegenerative diseases. The drug restored healthier sleep patterns and reduced brain damage in laboratory models of Alzheimer's disease. While these results are encouraging, it's important to note that Lemborexant is not yet approved for treating Alzheimer's disease. Further clinical studies in humans are needed to confirm these findings.
In summary, a recent study has shown that the insomnia medication Lemborexant, developed by Eisai, may have neuroprotective effects against Alzheimer's disease. The drug reduced tau buildup and preserved brain structure in preclinical models. However, more research is needed before Lemborexant can be considered a potential treatment for Alzheimer's disease.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
